Novo Nordisk A/S Securities Fraud Investigation Continues: Investors Urged to Contact Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP is investigating Novo Nordisk A/S (NVO) for possible violations of federal securities laws. The investigation follows the company's announcement of ending its partnership with Hims & Hers Health and cutting its guidance, citing lower growth expectations for Ozempic and Wegovy. Investors who lost money are urged to contact the law firm to inquire about potentially pursuing claims to recover their loss.

Novo Nordisk A/S (NVO) is under investigation by Glancy Prongay & Murray LLP for possible violations of federal securities laws, following a series of significant events that have impacted the company's stock price and investor confidence.

On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers Health, Inc. (HIMS), citing allegations of illegal mass compounding of weight-loss drugs and deceptive marketing tactics. This news led to a substantial decline in Novo Nordisk's stock price, falling $4.05, or 5.5%, to close at $69.72 per share [1].

Further exacerbating investor concerns, on July 29, 2025, Novo Nordisk revised its financial guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The company attributed this downward revision to slower-than-expected market expansion, competition, and the continued use of compounded GLP-1s. This announcement resulted in a significant stock price drop, with Novo Nordisk's shares falling $15.06, or 21.8%, to close at $53.94 per share [2].

The impact of these events has been profound, with Novo Nordisk's stock experiencing a $60 billion meltdown in a single day, five times the total market cap of Hims & Hers. Analysts have expressed concerns that the company may have underestimated the shift in the consumer health market and the potential of Hims to disrupt the market [2].

In response to these developments, Novo Nordisk has appointed a new CEO, Maziar Mike Doutsdar, and has seen a significant decline in trading volume, with a 44.84% drop on July 30, 2025, as investor anxiety heightened [3]. The company is scheduled to report its second-quarter earnings on August 6, 2025.

Investors who lost money on Novo Nordisk securities are urged to contact the Law Offices of Frank R. Cruz to inquire about potentially pursuing claims to recover their losses [1].

References:
[1] https://www.businesswire.com/news/home/20250730194386/en/Securities-Fraud-Investigation-Into-Novo-Nordisk-AS-NVO-Continues-Investors-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz
[2] https://investorsobserver.com/news/stock-update/novos-60-billion-meltdown-hims-breakup-backfires-as-weight-loss-rivals-surge/
[3] https://www.ainvest.com/news/novo-nordisk-3-33-billion-trading-volume-slides-top-3-stock-dives-7-25-ceo-profit-warning-2507/